Ontario fund invests $1 million in Interface Biologics

The Ontario Government’s Investment Accelerator Fund-Life Sciences (IAF-LS), which helps accelerate the growth of life sciences companies in Ontario, has invested $1 million in closely held Interface Biologics. “We are very pleased that the IAF-LS has chosen Interface as one of the limited number of life sciences companies they are funding,” Interface CEO Tom Reeves [...]

Interface in licensing pact with Navilyst Medical

Closely held Interface Biologics has reached a definitive license and supply agreement with Navilyst Medical, giving it exclusive access to incorporate Interface’s Endexo technology in its vascular access products. Navilyst Medical is a leading manufacturer of image-guided medical technologies. Endexo is a bio-medical polymer additive that results in a passivating surface that reduces platelet adhesion, [...]

Fresenius executes pact for Interface Biologics license

Fresenius Medical Care (NYSE:FMS), the world’s largest integrated provider of dialysis products and services, has executed an option for an exclusive license to apply Interface Biologics’ Endexo technology to various components of its dialysis circuits for treating end-stage renal disease, including dialyzers and blood lines. The original accord in July, 2010 provided for an eight-to-12 [...]

Interface names Rosenthal as chairman

Closely held Interface Biologics of Toronto has appointed Arthur Rosenthal as chairman of the board.  Dr. Rosenthal, who joined the Interface board in March, 2010, is currently CEO of Cappella, a medical device company focused on coronary artery disease. He has also held senior scientific and R&D titles at Boston Scientific, J&J Medical and CR [...]

Interface Biologics raises $7 million

Closely held Interface Biologics of Toronto has completed a $7 million series B financing, led by Business Development Bank of Canada, in conjunction with Covington Capital and VG Partners. “Based on our current forecasts, this financing is sufficient for us to reach cash flow breakeven but we are still open to a $3 million-to-$5 million [...]

Interface and BASF in business collaboration

Closely held Interface Biologics has signed a joint development agreement with BASF Future Business GmbH to collaborate in the development of new polymeric formulations, with antimicrobial and anti-thrombogenic properties. By joining Interface’s anti-thrombogenic technology with BASF’s proprietary anti-microbial technology platform, a combined effect can be achieved that will lead to new materials that can substantially improve the [...]

Interface gets ISO 13485:2003 certification

Closely held Interface Biologics has received ISO 13485:2003 certification, a quality management system that emphasizes design, process, quality and manufacturing reliability for medical device products. “Achieving certification to ISO 13485:2003 illustrates Interface’s commitment to quality for our customers, partners, and for the patients and healthcare providers who will rely on medical devices that incorporate our [...]

The deal’s the deal at Interface Biologics

Fresh from a potentially game-changing licensing deal with dialysis industry leader Fresenius Medical Care (FSE:FME; NYSE:FMS), closely held Interface Biologics still has more irons in the fire for its biomedical polymers to improve the safety and efficacy of blood-contacting medical devices. “What we’ve tried to do is select a few areas that represent big markets [...]

Interface Biologics licenses Endexo to Fresenius

Closely held Interface Biologics of Toronto has signed an evaluation and exclusive license option agreement with Germany’s Fresenius Medical Care (FSE:FME; NYSE:FMS), the world’s largest provider of dialysis products and services.  Under the accord, Fresenius will evaluate the use and efficacy of Interface’s Endexo technology to various components of its dialysis circuits for treating end-stage [...]

Interface Biologics CSO wins Julia Levy Award

Dr. Paul Santerre, a co-founder and CSO of closely held Interface Biologics, will receive the Julia Levy Award from the Canadian section of the Society of Chemical Industry on March 25. The Julia Levy award recognizes successful commercialization of innovation in Canada in the field of bio-medical science and engineering, with a particular focus on [...]

Next Page »